Clinical trials: Inadequate Glycaemic Control
Diabetes Mellitus, Type 2
Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus
This trial will compare the use of fixed dose combination of empagliflozin and linagliptin to linagliptin alone in patient with type 2 diabetes mellitus
- Trial name
- NCT02453555
- Testing
- Linagliptin, Empagliflozin + linagliptin low dose, Empagliflozin + linagliptin high dose
- Where
- 40 sites in Japan
- Volunteers
- 275 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Efficacy and Tolerability of Saxagliptin add-on Compared to Uptitration of Metformin in Patients With Type 2 Diabetes
The study will evaluate the efficacy and tolerability of saxagliptin compared to uptitration of metformin in patients with type 2 diabetes who have inadequate glycaemic control on a submaximal dose of metformin.
- Trial name
- PROMPT (NCT01006590)
- Testing
- Saxagliptin, Metformin
- Where
- 51 sites in Belgium, France and 5 more
- Volunteers
- 286 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control
A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination with Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin…
- Trial name
- NCT02273050
- Testing
- Saxagliptin 5 mg, Metformin 500 mg with titration
- Where
- 17 sites in China
- Volunteers
- 1,136 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Comprehensive Add on Study in Japan
The objective of the current study is to investigate the safety and efficacy of linagliptin (5mg / once daily) given for 52 weeks as add-on therapy to patients with type 2 diabetes mellitus and insufficient glycaemic control…
- Trial name
- NCT01204294
- Testing
- Linagliptin, Metformin
- Where
- 43 sites in Japan
- Volunteers
- 574 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus, Cardiovascular Disease
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease
This study is carried out to assess whether dapagliflozin improves glycemic control, decreases fasting plasma glucose levels, body weight and blood pressure when added to patient's existing medications and how it compares with…
- Conditions
- Type 2 Diabetes Mellitus, Cardiovascular Disease, Inadequate Glycaemic Control
- Trial name
- NCT01042977
- Testing
- Dapagliflozin
- Where
- 135 sites in United States, Argentina and 8 more
- Volunteers
- 964 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes
The purpose of this study is to assess safety and efficacy of empagliflozin compared to sitagliptin in patients with type 2 diabetes mellitus who are treatment-naive or on treatment with metformin and have insufficient glycaemic…
- Trial name
- NCT01984606
- Testing
- Empagliflozin, Sitagliptin
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus
The purpose of the study is to compare the effects on overall glycaemic control of two insulin intensification therapies.
- Trial name
- NCT01175811
- Testing
- Insulin Lispro Premix, Insulin Glargine, Insulin Lispro
- Where
- 14 sites in China, South Korea and 1 more
- Volunteers
- 402 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus, Inadequate Glycaemic Control
A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes
The aim of this study is to evaluate safety and efficacy of therapy with saxagliptin 5mg co-administered with dapagliflozin 5mg, compared to therapy with saxagliptin 5mg or dapagliflozin 5mg in patients who are inadequately…
- Trial name
- NCT02681094
- Testing
- Dapagliflozin, Saxagliptin
- Where
- 110 sites in United States, Canada and 4 more
- Volunteers
- 905 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Linagliptin Add-on to Insulin Background Therapy
To evaluate the efficacy and safety of linagliptin compared to placebo when added on to insulin therapy alone or in combination with metformin in Chinese patients with type 2 diabetes mellitus with insufficient glycaemic control
- Trial name
- NCT02897349
- Testing
- linagliptin, background therapy
- Where
- 25 sites in China
- Volunteers
- 206 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
The aim of this study is to investigate the efficacy, safety and tolerability of BI 10773 compared to placebo and sitagliptin given for 24 weeks as monotherapy in patients with T2DM with insufficient glycaemic control.
- Trial name
- NCT01177813
- Testing
- BI 10773, BI 10773 open label
- Where
- 124 sites in United States, Belgium and 7 more
- Volunteers
- 986 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Linagliptin as Add on to Basal Insulin in the Elderly
To investigate the efficacy, safety, and tolerability of linagliptin 5 milligrams once a day compared to placebo as as add-on therapy for 24 weeks to stable basal insulin treatment in elderly patients, 60 years of age and older…
- Trial name
- NCT02240680
- Testing
- linagliptin
- Where
- 145 sites in United States, Australia and 15 more
- Volunteers
- 302 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on Metformin
This study will evaluate the efficacy and tolerability of saxagliptin compared to glimepiride in elderly patients with type 2 diabetes mellitus who have inadequate glycaemic control on metformin monotherapy.
- Trial name
- GENERATION (NCT01006603)
- Testing
- Saxagliptin, Glimepiride
- Where
- 131 sites in Austria, Denmark and 11 more
- Volunteers
- 957 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to assess the efficacy of HSK7653 (as an add-on to metformin) compared with linagliptin after 24 weeks, and the safety (up to 52 weeks) of HSK7653 in Chinese patients with Type 2 Diabetes who have…
- Trial name
- NCT04564872
- Testing
- HSK7653 10 mg Q2W, HSK7653 25 mg Q2W, Linagliptin 5 mg QD
- Where
- 2 sites in China
- Volunteers
- 465 people
- Sponsor
- Sichuan Haisco Pharmaceutical Group Co., Ltd
Type 2 Diabetes
Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin
This study is being carried out to see if Dapagliflozin in addition to insulin is effective and safe in treating patients with type 2 diabetes when compared to placebo (identical looking inactive treatment) in addition to insulin
- Trial name
- NCT00673231
- Testing
- Dapagliflozin
- Where
- 92 sites in United States, Austria and 11 more
- Volunteers
- 1,240 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus, High HbA1c Level
Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
This study intends to compare the efficacy and safety of dapagliflozin versus placebo in patients with type 2 diabetes who have inadequate glycaemic control on a background combination of metformin and sulfonylurea.
- Conditions
- Type 2 Diabetes Mellitus, High HbA1c Level, Inadequate Glycaemic Control
- Trial name
- NCT01392677
- Testing
- dapagliflozin
- Where
- 42 sites in Canada, Czechia and 4 more
- Volunteers
- 311 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
The objective of the current study is to investigate the efficacy, safety and tolerability of Linagliptin (5 mg once daily) compared to placebo given for 24 weeks as add on therapy to metformin in combination with pioglitazone in…
- Trial name
- NCT00996658
- Testing
- Linagliptin
- Where
- 52 sites in United States, France and 2 more
- Volunteers
- 278 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus
This study is conducted to determine the most appropriate therapeutic doses of BI 10773 in Japanese patients with T2DM at first treatment period.
- Trial name
- NCT01193218
- Testing
- BI 10773
- Where
- 32 sites in Japan
- Volunteers
- 547 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
The objective of the study is to investigate the efficacy, safety and tolerability of linagliptin 5 mg qd compared to placebo given for 24 weeks in inadequately controlled T2DM patients on empagliflozin 10 mg or 25 mg and maximum…
- Trial name
- NCT01778049
- Testing
- BI 10773, BI 10773 / BI 1356
- Where
- 114 sites in United States, Argentina and 9 more
- Volunteers
- 708 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone
This study intends to compare the efficacy and safety of dapagliflozin versus placebo in treatment-naïve subjects with type 2 diabetes who have inadequate glycaemic control with diet and exercise alone.
- Trial name
- NCT01257412
- Testing
- Dapagliflozin
- Where
- 15 sites in India
- Volunteers
- 375 people
- Sponsor
- AstraZeneca